-
Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition
Tuesday, April 21, 2015 - 9:23am | 256Read More...Bernstein analyst Geoffrey Porges said it's time for Gilead Sciences, Inc. (NASDAQ: GILD) to continue the biotech M&A with a bid for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Porges noted that many investors "remain heavily exposed to mid and large cap biotech stocks"...
-
J.P. Morgan Comments On Vertex Collaboration
Tuesday, June 14, 2011 - 8:58am | 111Read More...According to J.P. Morgan, Vertex Pharmaceuticals (NASDAQ: VRTX) announced a WW collaboration with Alios Biopharma that would bolster its HCV pipeline by the addition of two nucleotide polymerase drugs (“nucs”; ALS-2200 and ALS-2158). J.P. Morgan said that these assets are very early stage (in...
-
J.P. Morgan Gives Update On VRTX
Friday, June 10, 2011 - 8:12am | 276Read More...J.P. Morgan is maintaining its Neutral rating and its $53 price target on Vertex Pharmaceuticals (NASDAQ: VRTX) following new data released by the company at the European Cystic Fibrosis Conference. According to J.P. Morgan, “We are attending the European Cystic Fibrosis (CF) conference in Germany...
